Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Arbor Biotechnologies is raising $214,999,926.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Devyn Smith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Arbor Biotechnologies
Arbor Biotechnologies is a life sciences company discovering and developing the next generation of genetic medicines based on wholly owned genomic editors discovered from its machine learning/AI driven discovery platform. Since its founding in 2016 by Feng Zhang, David Walt, David Scott and Winston Yan, Arbor has built the most extensive toolbox of proprietary genomic editors in the industry. Using the discovery platform, Arbor can discover, screen, and engineer novel editing enzymes and effectors that can then be tailored to the underlying cause of disease to result in potentially curative medicines for patients. As Arbor continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, the Company has also partnered with Vertex Pharmaceuticals on several gene editing and ex vivo cell therapy programs to broaden the reach of its novel nuclease technology.

To learn more about Arbor Biotechnologies, visit http://arbor.bio/

Contact:
Devyn Smith, Chief Executive Officer
860-287-7984
https://www.linkedin.com/in/devyn-smith-4a1441/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved